Catalog No.
Product Name
Application
Product Information
Citations
-
HIV-1 Inhibitor
BMS 488043 is an orally active inhibitor that targets the attachment process of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes. It exhibits strong antiviral activity by preventing viral entry, making it a valuable tool for research into HIV-1 transmission and infection dynamics. This compound is suitable for studies focusing on the development of therapeutic strategies against HIV-1. -
HIV-1 Inhibitor
Methyl salvionolate A is a potent inhibitor of HIV-1 that targets multiple viral enzymes. It demonstrates significant activity by inhibiting the production of P24 antigen in HIV-1 infected MT-4 cells with an EC50 value of 1.62 μg/ml. Additionally, Methyl salvionolate A effectively inhibits HIV-1 reverse transcriptase, protease, and integrase, with corresponding IC50 values of 50.58, 10.73, and 7.58 μg/ml, respectively. This compound is valuable for research into HIV-1 antiviral strategies and the development of therapeutic agents. -
HIV Nef Inhibitor
DLC27-14 is an HIV Nef inhibitor with an IC50 value of 15.92 μM, effectively disrupting the function of the Nef protein in HIV-1. This compound is valuable for research focused on HIV pathogenesis and exploring therapeutic strategies targeting viral replication. Its mechanism of action provides insights into the role of Nef in HIV dynamics and potential avenues for antiviral drug development. -
HIV-1 Inhibitor
TNK-651 is a non-nucleoside inhibitor of HIV-1 reverse transcriptase, effectively blocking viral replication. It demonstrates inhibitory activity against both the HIV-1 SF33 strain and the NNRTI-resistant HIV-1 A17 strain. TNK-651 is valuable for research applications focusing on HIV-1 infection and resistance mechanisms. -
CCR5 Antagonist
GSK-214096 is a selective CCR5 antagonist that inhibits HIV-1 entry through the blockade of the virus's glycoprotein 120 (gp120). By targeting the CCR5 co-receptor, this compound plays a critical role in interrupting HIV-1 infection pathways. It is valuable for research applications focused on HIV-1 biology and therapeutic discovery. -
Anti-HIV-1 Agent
HEPT is a potent and selective anti-HIV-1 agent that functions primarily by inhibiting viral replication. It targets the HIV-1 reverse transcriptase, disrupting the conversion of viral RNA into DNA, which is essential for viral propagation. This compound is valuable in HIV research for developing therapeutic strategies and studying the mechanisms of viral resistance. -
HIV Inhibitor
12-Methoxydodecanoic acid is an HIV inhibitor that exhibits anti-viral activity with an IC50 of 6.8 μM. This compound, a heteroatom-containing analog of myristic acid, has also been shown to inhibit the moloney murine leukemia virus (MoMLV). Its unique properties make it suitable for research into viral inhibition mechanisms and therapeutic development in HIV-related studies. -
HIV Inhibitor
GSK163929 is an orally bioavailable CCR5 antagonist, primarily targeting HIV infection. This compound demonstrates anti-HIV activity by inhibiting the CCR5 co-receptor, crucial for viral entry into host cells. GSK163929 has been evaluated for safety, showing no adverse effects in rat and dog models at specified dosages. Its properties make it a valuable tool for research in HIV therapies and co-receptor interaction studies. -
HIV-1 RT Inhibitor
L-697639 is a potent inhibitor of HIV-1 reverse transcriptase (HIV-1 RT), exhibiting an IC50 range of 20-400 nM in a template-primer-dependent manner. This compound demonstrates significant antiviral activity, effectively inhibiting up to 95% of HIV-1 infection in human T lymphocyte cultures at concentrations between 12-200 nM. L-697639 is a valuable tool for research applications focused on HIV-1 therapy and the mechanisms of viral replication. -
HIV gp120 Inhibitor
Chloropeptin I is an inhibitor of the HIV glycoprotein 120 (gp120), blocking its binding to the CD4 receptor with an IC50 of 2.0 μM. This compound exhibits selective anti-HIV activity, making it a valuable tool for research into HIV transmission and infection mechanisms. It serves as an important reagent for studying potential therapeutic strategies targeting HIV entry into host cells. -
Anti-HIV-1 Agent
BNM-III-170 free base is a CD4-mimetic compound that functions as an anti-HIV-1 agent. It binds to the Phe43 cavity of the HIV-1 gp120 protein, effectively inhibiting viral entry into target cells. This compound is valuable for research applications focused on HIV-1 infection and mechanisms of viral entry. -
HIV-1 Inhibitor
HIV-1-IN-86 is an HIV-1 inhibitor that targets viral replication. With an EC50 value of 0.77 μM, this compound exhibits significant antiviral activity against HIV-1. It is a valuable tool for research applications aimed at understanding HIV-1 biology and developing antiviral therapies. -
HIV-1 Protease Inhibitor
SDZ283-910 is a potent inhibitor of HIV-1 protease, targeting a crucial enzyme in the viral replication cycle. By disrupting the proteolytic processing of viral proteins, SDZ283-910 exhibits significant antiviral activity against HIV-1. This compound is valuable for research applications focused on understanding HIV biology and developing antiviral therapies. -
HIV-1 Inhibitor
HIV-1-IN-82 is a small-molecule entry inhibitor targeting HIV-1 with an IC50 value of 0.39 μM. This compound demonstrates potent antiviral activity, making it a valuable tool for research focused on anti-HIV-1 infection. It is suitable for studies investigating mechanisms of viral entry and the development of novel therapeutic strategies against HIV-1. -
HIV Inhibitor
GSK-364735 sodium is a potent inhibitor of the integrase enzyme of human immunodeficiency virus type 1 (HIV-1), demonstrating an IC50 value of 7.8 nM. As an antiretroviral agent, it serves as a valuable tool for studying HIV-1 replication and therapeutics. This compound is essential for researchers investigating integrase inhibition and its implications in HIV treatment strategies. -
HIV Integrase Inhibitor
PF-4776548 is a potent inhibitor of HIV integrase, a crucial enzyme in the integration of viral DNA into the host cell genome. By blocking this integration process, PF-4776548 demonstrates significant potential in the study of HIV replication and the mechanisms of AIDS pathogenesis. This compound is valuable for research applications aimed at developing antiviral strategies and understanding HIV-related diseases. -
HIV Inhibitor
Scirpusin A is a naturally derived compound from the legume Caragana rosea Turcz, recognized for its anti-HIV properties. It exhibits substantial inhibitory activity against HIV-1, with an effective concentration (EC50) of 7 μg/mL. Scirpusin A serves as a valuable tool in the research and development of novel anti-HIV therapeutics, contributing to the understanding of potential treatment options. -
HIV-1 Protease Inhibitor
LY-326188 is a potent inhibitor of HIV-1 protease, exhibiting an IC50 of 0.42 nM. It effectively protects HIV-1 infected cells from viral replication. This compound is valuable for research aimed at understanding HIV biology and developing antiviral therapeutics. -
HIV
rel-Carbovir monophosphate is the -enantiomer of 2',3'-dideoxy-2',3'-didehydroguanosine and a carbocyclic analog of carbovir. This compound acts as an inhibitor of HIV replication by specifically preventing the integration of proribonucleotides into viral DNA. It is primarily utilized in research applications related to HIV pathogenesis and therapeutic development. -
HIV Inhibitor
KRH-3955 is a potent CXCR4 antagonist that demonstrates significant anti-HIV-1 activity, particularly against X4 strains. It effectively inhibits the replication of various X4 HIV-1 clinical isolates and is active against recombinant strains with resistance mutations in reverse transcriptase, protease, and tyrosinase. KRH-3955 disrupts the binding of SDF-1alpha to CXCR4, thereby interfering with calcium signaling through this receptor, along with inhibiting antibody binding to CXCR4. With an oral bioavailability of 25.6% in rats, KRH-3955 has shown efficacy in vivo, making it a valuable tool for HIV research. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-15 is a selective inhibitor of HIV-1 protease, exhibiting a pIC50 value of 9.347. This compound effectively inhibits the maturation of HIV proteins, thereby blocking viral replication. It serves as a valuable tool for research on HIV-1 infection and potential therapeutic interventions. -
HIV-1 RT Inhibitor
7-Deaza-2',3'-dideoxyguanosine is an inhibitor of HIV-1 reverse transcriptase, functioning as a 2′,3′-dideoxynucleoside 5′-triphosphate. It demonstrates potent antiviral activity with an inhibition constant (Ki) of 25 nM, making it a valuable tool for research into HIV replication and reverse transcription processes. This compound is particularly useful for studies aimed at understanding the mechanisms of HIV resistance and the development of antiviral therapies. -
HIV Protease Inhibitor
MK-8718 is a potent and orally bioavailable HIV protease inhibitor that features a morpholine aspartate binding group. This compound effectively inhibits the activity of HIV protease, making it a valuable tool for studying HIV infection and antiretroviral therapy mechanisms. Its application in research may enhance the understanding of HIV replication and contribute to the development of novel therapeutic strategies. -
HIV Protease Inhibitor
PAC-Phe-Val is a potent inhibitor of HIV-1 protease, exhibiting an IC50 value of 33.10 nM. It establishes stable interactions with key active site residues, which enhances its inhibitory efficacy. This compound is suitable for research applications focused on HIV/AIDS and provides significant potential for therapeutic development in this area. -
HIV-1 Inhibitor
Hinokinin is a compound derived from the stems of Hypoestes aristata, primarily targeting the HIV-1 protease enzyme. It demonstrates moderate inhibitory activity against HIV-1, making it a potential candidate for antiviral research. This compound can be utilized in studies aimed at understanding the mechanisms of HIV-1 replication and developing therapeutic strategies against HIV infection. -
HIV protease inhibitor
Brecanavir is a potent inhibitor of HIV protease, a crucial enzyme in the HIV life cycle. By inhibiting this enzyme, Brecanavir effectively reduces viral replication, making it a valuable compound in HIV research and therapeutic development. Its potential applications include studying drug resistance mechanisms and exploring combination therapies for enhanced antiviral efficacy. -
Anti-HIV Nucleoside Reverse Transcriptase Inhibitor
CL-197 is a purine-based nucleoside reverse transcriptase inhibitor (NRTI) that exhibits anti-HIV activity through its selective inhibition of viral reverse transcriptase. This compound has potential applications in studying viral, oncological, and cerebrovascular diseases. Additionally, CL-197 serves as a click chemistry reagent, featuring an alkyne group that allows for copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules, facilitating advanced chemical research. -
HIV-1 Protease Inhibitor
TMC310911 is a potent and orally bioavailable inhibitor of the HIV-1 protease. It exhibits significant antiviral activity, with EC50 values ranging from 2.2 nM to 14.2 nM against wild-type HIV-1. Additionally, TMC310911 demonstrates effective activity against a broad range of recombinant HIV-1 isolates, making it a valuable tool for research on HIV-1 infection and resistance development. -
HIV Protease Inhibitor
Isoescin IA is a triterpenoid saponin derived from the seeds of Aesculus chinensis, functioning as an HIV protease inhibitor. This compound exhibits significant anti-HIV-1 protease activity, making it a valuable tool for research aimed at understanding HIV replication and potential therapeutic strategies. Its selective inhibition of the protease can aid in the investigation of antiviral mechanisms and drug development in the field of HIV research. -
HIV Protease Inhibitor
Ganodermanondiol is an HIV protease inhibitor derived from Ganoderma lucidum. It demonstrates significant anti-HIV-1 protease activity, with an IC50 of 90 μM, making it a valuable compound for antiviral research. Additionally, Ganodermanondiol exhibits strong cytoprotective effects against tert-butyl hydroperoxide-induced hepatotoxicity and showcases anticomplement activity against the classical pathway of the complement system, with an IC50 of 41.7 μM. This compound is relevant for studies focused on hepatoprotection and immune modulation. -
HIV-1 Protease Inhibitor
SKF107457 is a potent inhibitor of HIV-1 protease, a key enzyme critically involved in the viral replication process. This compound exhibits significant antiviral activity against HIV-1, making it valuable for studying the mechanisms of HIV infection and resistance. Additionally, SKF107457 can be utilized in research focused on developing new therapeutic strategies for AIDS. -
HIV Protease Substrate
HIV Protease Substrate IV is a specific substrate designed for HIV protease. It facilitates the quantitative assessment of HIV-1 protease activity, enabling researchers to study the enzyme's function and evaluate potential inhibitors. This substrate is particularly useful in the development of antiviral therapies targeting HIV protease, contributing to the understanding of HIV pathogenesis and treatment strategies. -
HIV-1p Inhibitor
NIT is an HIV-1 protease (HIV-1p) inhibitor, exhibiting Ki values of 96 μM for wild-type HIV-1p and 91 μM for multidrug-resistant HIV-1p. This compound demonstrates significant potential for studying HIV protease activity and developing therapeutic strategies against HIV infection. Its application in research may further elucidate mechanisms of viral resistance and aid in the design of more effective antiretroviral agents. -
HIV Protease Inhibitor
HIV-IN-11 is a potent HIV protease inhibitor that disrupts the activity of HIV-1 protease through competitive inhibition, with a Ki of 0.049 nM. This compound effectively inhibits the replication of HIV(IIIb)-infected MT4 lymphocytes at concentrations of 25.0-50.0 nM. Demonstrating a longer half-life compared to indinavir sulfate in animal models, HIV-IN-11 represents a promising candidate for second-generation HIV treatment research. -
HIV Protease Substrate
HIV-1, HIV-2 Protease Substrate is a specific substrate designed for the enzymatic activity of HIV-1 and HIV-2 proteases. This substrate contains four residues that allow for conservative substitutions, facilitating studies on substrate binding and protease activity. It is a valuable tool for research focused on HIV protease function and the development of antiviral therapies. -
HIV-1 Inhibitor
Mvt-101 is a hexapeptide-based inhibitor targeting HIV-1 protease. This compound functions as a reduced-peptide-bond inhibitor, effectively blocking protease activity and thereby inhibiting the replication of the HIV virus. Mvt-101 is particularly relevant for research in virology and therapeutics aimed at tackling HIV infection. -
HIV Protease Inhibitor
DMP 323 is a potent, nonpeptide cyclic urea inhibitor of HIV protease, targeting both HIV-1 and HIV-2. It functions as a competitive inhibitor by blocking the cleavage of peptide substrates and the HIV-1 gag polyprotein, demonstrating robust antiviral activity. DMP 323 exhibits comparable efficacy to leading HIV protease inhibitors while remaining effective in human plasma or serum, indicating low affinity for plasma proteins. Additionally, it shows minimal inhibition of mammalian proteases at higher concentrations, underscoring its selectivity for HIV protease. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-9 is a potent inhibitor of HIV-1 protease, exhibiting a Ki value of 0.028 nM. This compound demonstrates significant antiviral activity, with an IC50 of 66.8 nM, making it a valuable tool for research in HIV treatment and drug development. Its efficacy highlights its potential application in studies aiming to inhibit HIV replication and investigate resistance mechanisms. -
HIV-1 Protease Inhibitor
L-687908 is a highly potent HIV-1 protease inhibitor with a competitive inhibition constant (CIC95) of 12 nM. This compound effectively disrupts the proteolytic processing of viral polyproteins, thereby inhibiting viral replication. Its key biological activity makes it a valuable tool for antiviral research and the development of therapeutic agents targeting HIV-1. -
HIV Protease Inhibitor
AQ148 is a selective HIV-1 protease inhibitor with a Ki value of 137 nM. It demonstrates significant inhibitory activity against aspartic proteases from HIV-1 (IC50 = 1.5 μM), HIV-2 (IC50 = 3.4 μM), and simian immunodeficiency virus (SIV) (IC50 = 5 μM). This compound is useful for research applications focused on HIV pathogenesis and the development of antiviral therapies. -
HIV Protease Inhibitor
20(21)-Dehydrolucidenic acid A is a triterpenoid derived from the fruiting body of Ganoderma sinense, primarily targeting HIV protease. This compound exhibits modest inhibitory activity against HIV-1 protease, making it a valuable tool in the study of HIV pathogenesis and in the development of antiviral strategies. Its unique structure offers potential insights into therapeutic applications for HIV treatment. -
HIV Protease Inhibitor
U-85548E is an HIV protease inhibitor that demonstrates nanomolar affinity for the HIV-1 aspartic protease. This compound has been developed through investigations into its structure-activity relationships, proving effective against both HIV-1 and HIV-2 proteases. Its binding interactions have been characterized using X-ray crystallography and molecular modeling, making it a valuable tool for research in HIV drug development and mechanistic studies of protease inhibition. -
HIV Protease Substrate
HIV Protease Substrate 1 is a fluorogenic substrate specifically designed for the study of HIV protease activity. This reagent allows for the quantitative assessment of enzymatic function, facilitating investigations into HIV protease inhibitors and their effects on viral replication. It is particularly useful in the development of antiviral therapies and for studying the proteolytic processing of HIV proteins. -
HIV-1 Protease Inhibitor
JE-2178 is an orally bioavailable inhibitor of HIV-1 protease, exhibiting potent antiviral activity. With an IC50 value of 15 nM and a Ki value of 0.318 nM, JE-2178 effectively targets the protease enzyme critical for viral replication. This compound is valuable for research applications focused on HIV-1 inhibition and the development of antiretroviral therapies. -
HIV-1 Protease Substrate
HIV Protease Substrate I is a chromogenic substrate specifically designed for the HIV-1 protease. It contains the optimal cleavage site recognized by the enzyme, enabling accurate assessment of protease activity. This substrate is valuable for studying HIV-1 protease function and kinetics, as well as for evaluating the efficacy of protease inhibitors in research applications. -
HIV-1 Protease Inhibitor
HIV-1 protease-IN-7 is a selective inhibitor of the HIV-1 protease, exhibiting an IC50 of 3.52 nM and an EC50 of 37 nM. This compound demonstrates potent antiviral activity, making it a valuable tool in the study of HIV-1 replication and protease function. Its efficacy positions it as a useful reagent for research applications aimed at developing antiviral therapies against HIV-1. -
HIV Protease Inhibitor
Kynostatin 272 is a potent inhibitor of the HIV protease, targeting the enzyme's active site by mimicking the substrate transition state. This mechanism effectively disrupts a critical stage in the replication cycle of the HIV virus. Kynostatin 272 serves as a valuable tool in HIV research, aiding in the development of therapeutic strategies for managing HIV and AIDS. -
HIV Protease Inhibitor
Stercobilin hydrochloride (mixture of isomers) serves as an HIV protease inhibitor, exhibiting a Ki value of 4 μM. This bile pigment, derived from gut bacteria metabolism, can promote pro-inflammatory responses in mouse macrophage RAW264 cells, including the upregulation of cytokines such as TNF-α and IL-1β. Applications of Stercobilin hydrochloride extend to the investigation of inflammatory processes and viral infections. -
HIV Protease Inhibitor
GS-9770 is an orally active inhibitor specifically targeting HIV protease, with a Ki of 0.16 nM. It demonstrates potent antiviral activity against both HIV-1 and HIV-2 strains, showing EC50 values ranging from 1.9 to 26 nM. In addition to its efficacy, GS-9770 is metabolically stable in human liver microsomes and exhibits favorable pharmacokinetic properties in Sprague Dawley rats, making it a valuable tool for research in HIV treatment. -
HIV Protease Inhibitor
L 756423 is a potent inhibitor of HIV protease, targeting the enzyme crucial for the maturation of infectious HIV particles. This compound exhibits significant antiviral activity, making it a valuable tool for research into HIV infection and the development of therapeutic strategies. Its effective inhibition of protease could contribute to understanding HIV lifecycle and resistance mechanisms.
